Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Other Accumulated Expenses (2016 - 2021)

vTv Therapeutics' Other Accumulated Expenses history spans 8 years, with the latest figure at $155000.0 for Q4 2021.

  • For Q4 2021, Other Accumulated Expenses rose 675.0% year-over-year to $155000.0; the TTM value through Dec 2021 reached $155000.0, up 675.0%, while the annual FY2021 figure was $155000.0, 675.0% up from the prior year.
  • Other Accumulated Expenses for Q4 2021 was $155000.0 at vTv Therapeutics, up from $20000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $1.1 million in Q4 2017 and bottomed at $20000.0 in Q4 2020.
  • The 5-year median for Other Accumulated Expenses is $142000.0 (2018), against an average of $300400.0.
  • The largest annual shift saw Other Accumulated Expenses tumbled 86.55% in 2018 before it soared 675.0% in 2021.
  • A 5-year view of Other Accumulated Expenses shows it stood at $1.1 million in 2017, then crashed by 86.55% to $142000.0 in 2018, then fell by 9.15% to $129000.0 in 2019, then crashed by 84.5% to $20000.0 in 2020, then skyrocketed by 675.0% to $155000.0 in 2021.
  • Per Business Quant, the three most recent readings for VTVT's Other Accumulated Expenses are $155000.0 (Q4 2021), $20000.0 (Q4 2020), and $129000.0 (Q4 2019).